Mapp Biopharmaceutical, Inc.

Mapp Biopharmaceutical, Inc.

We develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.

In the News

[recent_posts before=”” image=”true” headline=”true” text=”” readmore=”true” after=”” number=”3″ column=””]

PBS NewsHour – How to grow an Ebola vaccine with a tobacco plant November 23, 2015

Publications

Passive immunization with an extended half-life monoclonal antibody protects Rhesus macaques against aerosolized ricin toxin. Feb 13, 2020

Rescue of rhesus macaques from the lethality of aerosolized ricin toxin. Jan 10, 2019

A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates. Jan 9, 2019

Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection. Jan 9, 2019

Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Apr 05, 2017

Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses,. Apr, 2017

De Novo MS/MS Sequencing of Native Human Antibodies. Oct 25, 2016

A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. Oct 13, 2016

Monoclonal antibody therapy for Junin virus infection. Apr 4, 2016

Antibody therapeutics for Ebola virus disease. January 27, 2016